Vašemu vyhledávání neodpovídají žádné výsledky.
Abyste našli to, co hledáte, doporučujeme vyzkoušet následující postup:
Last year, Informa Pharma Intelligence and Oracle surveyed the Life Sciences industry to understand the impact of the COVID-19 pandemic on clinical trial management and found the industry rapidly shifting to decentralized clinical trial methods, while balancing concern around data quality and regulatory compliance. Now, a year later, we tap the industry again to explore clinical trial management in a post-pandemic world.
To investigate this, Informa Pharma Intelligence and Oracle surveyed professionals involved in clinical trials at biopharmaceutical companies, medical device companies, and contract research organizations (CROs) based around the world to understand the adaptations that have been made to clinical trials, the effect of these adaptations, and the impact of these changes on the future of clinical trials.
The research results provide valuable insight into the lasting and positive impact of the adaptations made during the pandemic and reveal an industry embracing change.
82% of respondents who implemented new clinical trial approaches during the pandemic report they have had a positive impact on clinical trials overall, including 26% reporting a “significantly” positive impact.
92% of respondents who implemented new clinical trial methods during the pandemic are equally or more confident in the data collected from these methods, compared to data collected via prepandemic methods.
97% respondents who implemented new clinical trial methods during the pandemic indicated their organization will continue using at least one of these new methods.
In last year’s industry survey conducted by Informa Pharma Intelligence and Oracle, 76% of respondents indicated that the COVID-19 pandemic had accelerated their adoption of decentralized clinical trial methods.
This research was conducted by Informa Engage, on behalf of Oracle. Data was collected from July 14 through September 16, 2021. The research methodology used conformed to accepted marketing research methods, practices, and procedures. The research was conducted through an online survey sent to Informa Pharma Intelligence subscribers around the world who work in organizations involved in clinical research. Only respondents who worked for biopharmaceuticals, CROs, and medical device companies qualified to participate.
The vast majority of respondents were from biopharmaceutical companies (76%), with the balance representing medical device companies and CROs.
See why the industry is confident in new clinical trial methods.
The COVID-19 pandemic radically changed the world in an instant and forced adaption across the board. Some industries, such as retail, hospitality, and transportation, screeched to a halt, while others, such as healthcare, had to immediately adapt to support the overwhelming human crisis caused by COVID-19.
In the life sciences industry, those conducting clinical trials had to quickly adjust to new ways of monitoring and caring for clinical trial participants in a world where physical access was not an option. Many data collection methods that have been available for years but not widely used were suddenly adopted at scale in clinical trials during the pandemic.
A decisive majority of respondents (84%) reported implementing alternative approaches in order to continue existing clinical trials and/or to start new trials during the COVID-19 pandemic.
Those who did not do so were most likely to indicate they had already adopted pandemic-compatible approaches prior to the onset of COVID-19 (49%).
A wide variety of alternative approaches in clinical trials were implemented during the pandemic, with the most common being remote monitoring, video visits, phone visits, eConsent, and EHR. While many of these approaches have been around for several years, the COVID-19 pandemic served as a catalyst for adoption.
Digging into this a bit deeper, the survey revealed that 82% of respondents feel that the new clinical trial approaches they adopted during the pandemic have had a positive impact on clinical trials overall, including 26% reporting a “significantly” positive impact.
When asked about the specific ways in which the newly adopted approaches had a positive impact on clinical trials, many outcomes were cited, with the most common being more timely data, improved flexibility for patients, and increased speed.
With the introduction of new approaches and technology in clinical trials—especially those related to remote data collection from patients—comes an increase in data volume and variety. As such, it is not surprising that many of the positive impacts of clinical trial approaches newly implemented during the pandemic relate to data. As shared in the table above, respondents using new methods in clinical trials found their data to be more timely, higher quality, more frequent, and more robust.
But the big question is: do study teams find all this additional data useful and do they have confidence in it?
The great news is that the vast majority of survey respondents (87%) reported being able to use “most” or “all” of the additional data their newly implemented approaches have generated.
And, when asked about their confidence in the data, most (81%) have high confidence in this additional data, including 30% who report “complete” confidence.
Even more compelling, when asked about their confidence in the data generated by newly adopted approaches versus data generated by prepandemic methods, 92% of respondents who implemented new clinical trial methods during the pandemic are equally or more confident in the data collected from these methods, compared to data collected via prepandemic methods.
Learn what new clinical trial methods will continue in the post-pandemic world.
While the COVID-19 pandemic forced change in the way clinical trials were conducted and managed, the question is—will these changes remain? And what does this mean for the future of clinical trials?
Based on the results of this research, these newly adopted clinical trial methods are here to stay. Of the respondents who implemented new clinical trial methods during the pandemic, 97% indicated their organization will continue using at least one of these new methods, with remote monitoring, video visits, EHR, and phone visits being the approaches most likely to continue.
When probed regarding the effects of continuing to use newly implemented approaches in clinical trials, more complex work for investigators and site staff (37%) and increased volume of data (36%) emerged as the most significant consequences.
The adoption of new clinical trial approaches reflects the movement on the continuum of clinical trial models from site-based to decentralized, which occurred during the pandemic—but what shifts are expected going forward?
Survey respondents who implemented new clinical trial methods during the pandemic expect their organizations to increase their use of hybrid (44%) and fit-for-purpose (42%) models after the pandemic. Of the four models considered—site-based, fit-for-purpose, hybrid, and decentralized—respondents expect the use of the site-based model to decrease the most (24%).
Of those survey respondents who expect an increase in fit-for-purpose, hybrid, and/or decentralized clinical trial models going forward, most expect these models will be used for both existing trial restarts (63%) and new trials (61%).
As noted earlier, the top three positive outcomes resulting from the adoption of new clinical trial methods during the pandemic were more timely data, improved flexibility for patients, and increased speed. Interestingly, the importance of improving the patient experience emerged again when survey respondents were asked whether their organization planned to give patients the option to choose how they participate in clinical trials.
A slight majority of respondents (58%) said that their organizations plan to give patients the option to choose how they participate in clinical trials. Most respondents believe allowing patients a choice will have a positive impact on clinical research (61%).
Last year, in the throes of the COVID-19 pandemic, we saw industries adapt and evolve in rapid fashion in response to an environment never experienced before. People, organizations, and industries came together, got creative, and left their comfort zones in order to survive.
For those involved in clinical trials, that meant quickly adjusting to support alternative ways of monitoring and caring for clinical trial participants in a world where traditional, in-person methods were no longer an option. The pandemic accelerated the adoption of new approaches, technology, and models—many of which were being cautiously explored and piloted before—at scale.
The COVID-19 pandemic challenged status quo and served as a catalyst for the adoption of the technology-enabled ‘patient-centric’ decentralized clinical trials model. As data overflowed from diverse sources, data collection models transitioned from ‘discrete’ data points to ‘continuous’ measures and from ‘local optimums’ to unified cloud-native platforms. The reality of this shift to the new norm has led to most of the industry planning on continuing to implement newer decentralized clinical trial models, with a significant reduction in the traditional site-based model. It is evident that patient optionality rules the day, with most organizations planning on giving patients the choice about how they participate in clinical trials.
—Nimita Limaye, Research Vice President, IDC
While this forced change was disruptive and surely worrisome, the impact of these changes, as we emerge from the pandemic, is overwhelmingly seen as positive. The results of this survey revealed:
Additionally, the forced adoption of fit-for-purpose, hybrid, and decentralized clinical trial models during the pandemic has helped the industry understand when and how to implement these approaches to improve clinical research. This is reflected in the results of this survey, with respondents expecting the continued use of these models in the post-pandemic world and giving patients the option to choose how they participate in clinical trials.
Fortunately, the technology and software to support these changes in clinical research exists today, and are designed to carry the industry into the future of clinical trials. As approaches to clinical trials continue to evolve, study teams can rest assured that technology will not slow them down.
Unify people, processes, and data with Clinical One.